Classification of cirrhotic patient samples based on imaging MS of multiplexed N-glycan markers in biofluids.
This poster is an example of how Aspect Analytics can be your partner to develop specialized bioinformatic and data analysis workflows for your specific use-case or application.
The GlycoTyper assay was developed by GlycoPath LLC to profile N-glycans from patient biofluids. The assay utilises an antibody array to capture biofluid glycoproteins, with N-glycans subsequently released via enzymatic digestion and detected via MALDI-MSI. GlycoPath partnered with Aspect Analytics to develop a data analysis workflow to automate different steps and aid transfer of the assay from a research setting to more high-throughput environments.
Proof-of-concept data analysis workflow.
The workflow consists of MSI data and metadata inventorization and analysis, automated extraction of MSI spot data and machine learning methods for exploration and patient classification. When applied to measurements from a preliminary cohort of patients with either early- or late-stage liver cirrhosis, the resulting models were able to confidently distinguish between the two clinical states based on serum N-glycan profiles
Nico Verbeeck1, Danielle A Scott2, Alice Ly1, Stephen Castellino2, Richard R Drake2,3, Peggi M Angel2,3, Anand S Mehta2,3, Marc Claesen1. Classification of cirrhotic patient samples based on imaging MS of multiplexed N-glycan markers in biofluids., 70th ASMS Conference on Mass Spectrometry and Allied Topics, Minneapolis, Minnesota, USA, 2022
Aspect Analytics NV, Genk, Belgium
Glycopath Inc., Charleston, SC
Medical University of South Carolina, Charleston, SC